The U.S. Food and Drug Administration (FDA) approves daraxonrasib, a first-in-class, once-daily pill for treating advanced pancreatic cancer. Multiple outlets report that patients taking daraxonrasib live substantially longer than those receiving standard chemotherapy in a key clinical trial.
The drug is described as targeting a mutated protein that drives tumor growth, reported by several sources to be present in more than 90% of pancreatic cancer cases. The FDA grants expedited approval, and CBS, The Hill, and other outlets describe the approval as applying to patients whose disease has progressed after prior treatment (with specifics varying by outlet’s wording). The Conversation and BBC present the approval as a major step for a cancer with poor survival rates, while The Hill and CBS focus more on the trial outcomes and eligibility. CBS cites median survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, while other outlets summarize the same effect as roughly doubling survival.
